

## D6.1 – Dissemination and Communication Plan

ISCIH (P5) & ECSA-HC (P11)

Project Acronym	EU-Africa PerMed	
Project Title	BUILDING LINKS BETWEEN EUROPE AND AFRICA IN PERSONALISED MEDICINE	
Grant Agreement no.	964333	
Start date of the project	01/02/2021	
End date of the project	31/01/2025	
Work Package number	WP6 – Communication and Dissemination	
Deliverable Number	D6.1	
Deliverable title	Dissemination and Communication Plan	
Lead Beneficiary	ISCIII (P5) & ECSA-HC (P11)	
Due date	M6 (June 2021)	
Date of delivery	30 <sup>th</sup> June 2021	
Nature	R (Report)	
Dissemination level	PU (Public)	
DISCLAIMER This document reflects only the author's view. Responsibility for the information and views expressed therein lies entirely with the authors. The European Commission is not responsible for any use that may be made of the information it contains.		
Version	Contributors	Comments
V1. 07/06//2021	Marta Serrano & Esther Rodríguez (ISCIII)	
V2. 17/06/2021	Nomsa Mulima (ECSA-HC), Erika Sela (INNO), Monika Frenkel (ANR), Maria José Ruiz (IT MoH), Teresia Nyawira (NACOSTI),	
VF. 22/06/2021	-	



## TABLE OF CONTENT

1. OBJECTIVE .....	3
2. METHODOLOGY.....	3
2.1. METHODOLOGY .....	3
2.2. IDENTIFIED TARGET GROUPS: STAKEHOLDER MAPPING .....	3
2.3. VISUAL IDENTITY.....	5
2.4. PROJECT LAUNCH.....	5
2.5. DISSEMINATION TOOLS AND CHANNELS .....	7
2.6. TIMEFRAME.....	11
3. INTERNAL COMMUNICATION .....	11
4. MONITORING OF THE DISSEMINATION AND COMMUNICATION.....	13
4.1. KEY PERFORMANCE INDICATORS.....	13
4.2. D&C MONITORING PROTOCOL .....	13
4.3. OBLIGATIONS FOR COMMUNICATION ACTIONS.....	14
5. CONCLUSIONS AND NEXT STEPS.....	14
ANNEXES.....	15

## Executive summary

The **EU-Africa PerMed** project's objective is to integrate African countries into ICPeMed (International Consortium of Personalised Medicine), fostering joint PM projects and programmes between Europe and Africa, strengthening bilateral EU-AU Science, Technology and Innovation (STI) relations in the area of health, as means to contribute to a successful implementation of Personalised Medicine in the global context.

This deliverable outlines the strategy for dissemination and communication activities that will be carried out during the project, under the framework of Work Package 6.

The aim of task 6.1 is to elaborate the communication strategy, starting with the identification of target audiences, the communication channels that will ensure to reach them as well as a mapping of the most relevant events where EU-Africa PerMed should be present.

Some activities have already been completed, such as the launch of the project website and the publication of a short news announcing the project starting as well as the kick off meeting celebration last March 2021.

Internal communication procedures have also been established. In order to facilitate the D&C by all the partners, a D&C Tool kit has been prepared, with some guidelines and materials to be used.

To conclude, indicators have been set up, and these will be monitored by WP6 leaders (ISCIII & ECSA-HC), so the D&C activities can be reinforced if needed.



## 1. Objective

According to the WP6 description, the specific objectives of the Communication and Dissemination activities are:

- To raise awareness of the project and outcomes among all relevant stakeholders (e.g. via a newsletter, press releases, twitter, exchange with other initiatives by presenting the project, etc.)
- To ensure timely engagement and continuous interactions with relevant stakeholders
- To carry out dissemination actions to ensure that relevant stakeholders receive and understand the main findings and results of the project

## 2. Methodology

### 2.1. Methodology

The diverse nature of the EU-Africa PerMed has to be acknowledged and the different activities, channels and tone of message will be used. Communication in and around EU-Africa PerMed will occur at the following levels:

- a) Between partners of the consortium, by regular phone calls, emails, face-to-face and virtual meetings, and workshops.
- b) With stakeholders closely engaged with the project, such as the External Advisory Board, ICPeMed and ERA PerMed projects, speakers and attendees to the summer schools and other workshops, through emails, face-to-face and virtual meetings/workshops.
- c) Interested public, scientific community, policy-makers, health-related funding entities, healthcare providers, industry, patients' associations and other from the civil society, etc (as can be seen in the following section 2.2, this audience group has been further segmented)
- d) EU Commission services, project officer.

The gathering of information concerning the identification of relevant stakeholders will be mainly made through two different means:

1. Surveys and questionnaires addressed to the partners of the consortia
2. Fed by the stakeholders mapping, within WP2 (deliverable D2.1)

Some of the target stakeholders were already identified during the proposal preparation phase, while others have been added as a result of surveys and the stakeholders mapping elaborated by WP2 leaders (INNO & ECITD).

### 2.2. Identified target groups: stakeholder mapping

The following table (table 1) shows only some relevant examples of the stakeholders identified. The complete table has more than 150 entries so far, and it is expected that it will continuously grow as the project evolves. Some of the organisations can be included in two groups, i.e., the health ministries that can be classified as health research funders as well as health systems policy makers.



Table 1 – Example of the stakeholders identified (complete information on D2.1 Stakeholders' mapping)

Organisation	Region	Type of stakeholders
GROUP 1 – Health research organisations (including Universities and private-public initiatives)		
South African Medical Research Council	South Africa	1.1. University research groups 1.2. Research centres/institutions 1.3. Private-public partnerships 1.4. Biobanks 1.5. Ethics Councils and committees 1.6. Research consortium and networks 1.7. Regulators 1.8. Societies of Human Genetics
University of Cape Town	South Africa	
Joint Clinical Research Centre	Uganda	
African Academy of Sciences	Kenia	
GROUP 2 – Research and innovation funders		
National Council for Science and Technology NCST	Rwanda	2.1. Science/ granting councils 2.2. Research funding agencies, 2.3. Science & Technology ministries 2.4. Private foundations 2.5. Multilateral funding agencies 2.6. African Academy of Science
National Council for Science Research Council	Uganda	
Research Council	Zimbabwe	
Ministry of Environment, Science, Technology and Innovation	Ghana	
EDCTP	South Africa & The Netherlands	
H3Africa Human Heredity & Health in Africa	South Africa	
GROUP 3 – Health system policy makers		
Ministry of the public Health	Niger	3.1. Health ministries 3.2. International organizations 3.4. Regional Agencies 3.5. Science & Technology ministries 3.6. Regulators
Department of Health	South Africa	
South African Health Products Regulatory Authority	South Africa	
Pharmacy and Poisons Board of Kenya	Kenya	
The Food & Drugs Authority (FDA)	Ghana	
GROUP 4 – Healthcare providers		
National public health laboratories	Kenya	4.1. Hospitals 4.2. Laboratory facilities/ infrastructure
Medical Research Institute (MASRI), Ain Shams University	Egypt	
Centre Hospitalier Universitaire De Kigali	Rwanda	
GROUP 5 – Industry and private businesses		
Roche Pharmaceuticals Ghana	Ghana	5.1. Pharmaceutical companies 5.2. Biotech companies 5.3. Genomic testing companies 5.4. Diagnostic Laboratories 5.5. Technology suppliers 5.6. Medical insurers 5.7. Health Data companies 5.8. Health incubators
Gknowmix Partnership	South Africa	
Data Clean	Egypt	
Dell Technologies	Ghana	
Inqaba Biotech West Africa Ltd	Nigeria	
Inqaba Biotec East Africa Ltd	Tanzania	
GROUP 6 – Civil society organisations		
Cancer Association South Africa (CANSA)	South Africa	6.1. Patient groups 6.2. Advocacy groups



In order to accomplish each specific objective of the project, different target groups will be addressed:

Table 2 – Target group by specific objective to be accomplished

GROUP / SPECIFIC OBJECTIVE	SO 1 – Integrate African countries into ICPeMed	SO2 – carry out capacity building activities	SO3- contribute to support EU-African policy
GROUP 1 – health research organisations			
GROUP 2 – research and innovation funders			
GROUP 3 – health system policy makers			
GROUP 4 – healthcare providers			
GROUP 5 – industry and private businesses			
GROUP 6 – civil society organisations			

### 2.3. Visual identity

The image and format of the project materials will be standardised so EU-Africa PerMed has its own visual identity. The logo has been designed by Innovatec, through consultation with partners among two options and confirming the most voted one.




Figure 1- Project logos

Visual identity has been as well considered for elaborating templates for multiple purposes such as presentations and deliverables (included in the D&C Toolkit).

### 2.4. Project launch

The first action taken was the announcement of the project launch through the communication channels already established. A short [press release](#) was prepared by WP6 leaders and distributed among the partners so they could use their own communication channels to disseminate basic information on the project: objective, EU funding, partners, timeframe, role in the project, etc.

Partner	Link
ANR (P4)	<a href="#">ANR website</a>
ECRIN (P3)	<a href="#">ECRIN website</a>
MoH IT (P2)	<a href="#">IRIS Magazine</a>
ISCIH (P5)	<a href="#">ISCIH website</a>
ECSCA-HC (P11)	<a href="#">ECSCA website</a>
NACOSTI (P12)	<a href="#">NACOSTI website</a>
APHRC (P10)	<a href="#">APHRC website</a>
ICPeMed - external	<a href="#">ICPeMed website</a>





Figure 2 – Screenshots of the EU-Africa PerMed announcements



EU-Africa PerMed has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 964333

All the partners were requested to complete a survey on the most relevant events that will take place in 2021. Related events are useful to give visibility to the project, as well as to get new contacts of entities or experts that could be interested in joining the events that will be organised under the frame of the project or even participate as speakers.

The following table shows the relevant events gathered so far:

*Table 3 – Relevant events in 2021*

Name/Topic	Organiser	Date	Comment
Webinar “Systems Biology & Personalised Medicine”	EULAC PerMed Project	21 May	
European Partnership for Personalised Medicine Information Day	ICPerMed / ERA PerMed project	31 May	Free for all, but requires registration
Africa-Europe Science and Innovation Summit	The Africa-Europe Science Collaboration Astronomy Platform (AERAP)	15-17 June 2021	The project will be represented by ANR, who will participate in one session: Genomics for Shared Research and Better Health Outcomes
Webinar “Horizon Europe funding programme: focus on Personalised Medicine”	EULAC PerMed Project	13 July	
Biennial EDCTP Forum <a href="#">Equity in Research for Health</a>	EDCTP	17-21 Oct	
ICPerMed family event – close meeting but opened to EU-Africa PerMed partners)	ICPerMed	9-10 Nov	Partners will be invited to attend

## 2.5. Dissemination tools and channels

### Newsletters

One newsletter will be elaborated every 6 months. ECSA-HC (P11) will be responsible of elaborating and distributing them among those who have subscribed through the corresponding link available on the project website. The rest of the partners will be asked to provide content to be included as well.

In the same way, updated information on EU-Africa PerMed project will be included in the newsletter of related initiatives, such as ICPerMed, ERA PerMed or EULAC PerMed.



Table 4 - Planned press releases and expected date

Press release	Event	Expected month
#1	Kick off meeting	M1 (released)
#2	Stakeholder workshop 1	M12
#3	First Summer School + Stakeholder Workshop 2	M25
#4	Second Summer School	M31
#5	Stakeholder workshop 3	M44
#6	Project end	M48

Press releases will be sent to national and regional media. They will be released coinciding with relevant events. The first press release was published after the kick off meeting of the project.

An example is the publication in the April edition of the [IRIS Magazine](#), an Italian magazine dedicated to health policy and research.

### Short input papers

They will be elaborated for feeding the EU-AU policy dialogue (task 4.3). They will gather the main outcomes of the workshops and meetings, and, unlike the press releases and newsletters, will be specifically targeted to policy makers.

### Project brochure

A project brochure has been elaborated and included in the D&C Toolkit. In digital format, it can be easily distributed and used to have the basic information of the project. As the project evolves, the brochure will be updated with relevant information. It is expected to update the brochure by M22. This way, it will also announce the next stakeholders' workshops that will take place by M25.



**BUILDING LINKS BETWEEN EUROPE  
AND AFRICA IN PERSONALISED  
MEDICINE**

01/02/2021- 31/01/2025

2 million euros

Coordination and Support Action

INNOVATEC (ES)



#### OBJECTIVE:

To integrate African countries into the [International Consortium of Personalised Medicine](https://www.icpermed.eu/) (<https://www.icpermed.eu/>) activities as a means to contribute to a successful implementation of [Personalized Medicine](#) in the [global context](#), fostering joint [PM projects and programmes](#) between [Europe and Africa](#), as well as strengthening bilateral [science, technology and innovation](#) relations in the area of health.

Figure 3 – Part of EU-Africa PerMed brochure (Annex IV)



## Website

The project website has been already launched (<https://www.euafrica-permed.eu/>).

It will be frequently updated with project results and activities. The public deliverables will also hosted in a specific section for downloadable materials, and it will serve as a platform to announce workshops and summer schools.



Figure 4- Website screenshot

## Social media

Social Media is identified as one of the simplest and also more effective when sharing information and raising awareness on the project. With this purpose, a twitter account has been opened @EU\_AfricaPerMed. Project-related information will be posted under hashtag #EU\_AfricaPerMed.



Figure 5 – Screenshot of EU-Africa PerMed twitter profile

Also, communications channels of other related initiatives will be used. Find below a table with the most relevant projects identified. They will be addressed to announce the project launch, present the specific objectives and seek potential ways of collaboration. Some of the partners of EU-Africa PerMed Consortium are already involved in other related initiatives, which will facilitate the approach and collaboration.



Table 5 – Related projects/programmes or initiatives

Name	Topic	Link	Action
EULAC PerMed	Widening EU-LAC policy and research cooperation in Personalised Medicine	<a href="http://eulac-permed.eu/">eulac-permed.eu/</a>	Contacted – EU-Africa PerMed short notice to be included in next newsletter
ERA PerMed	funding programme for research projects in Personalised Medicine	<a href="http://erapermed.isciii.es/">erapermed.isciii.es/</a>	Contacted – EU-Africa PerMed short notice to be included in July newsletter
ICPerMed	The International Consortium for Personalised Medicine	<a href="http://icpermed.eu/index.php">icpermed.eu/index.php</a>	Contacted – EU-Africa PerMed launch was announced in ICPerMed website EU-Africa PerMed is presented on the ICPerMed website “ICPerMed family”
EU-Stands4PM	Develop relevant standards for in silico approaches in personalised medicine / pan-European expert forum and framework	<a href="http://eu-stands4pm.eu/">eu-stands4pm.eu/</a>	
PERMIT	Developing recommendations for more robust and reproducible personalised medicine research	<a href="http://permit-eu.org/">permit-eu.org/</a>	
H3Africa	H3Africa facilitates fundamental research into diseases on the African continent	<a href="http://h3africa.org">h3africa.org</a>	Contacted through Member of the A. Board
H3ABionet	Pan African Bioinformatics Network for the Human Heredity and Health in Africa (H3Africa) consortium.	<a href="https://www.h3abionet.org/">https://www.h3abionet.org/</a>	
RicercitaliaAfrica	The Italian research partnership with Africa: a survey on ongoing projects	<a href="http://www.iss.it">www.iss.it</a>	
AESA	The Alliance for Accelerating Excellence in Science in Africa	<a href="https://www.aasciences.africa/aesa">https://www.aasciences.africa/aesa</a>	

### Videos

Two short videos (2-3 minutes) will be prepared.

It is expected that as part of WP4 activities, the consortium will organize bilateral meetings (face to face or web meetings) with organizations interested in ICPerMed and ERA PerMed.




Table 6 summarises the D&C activities that will be used for reaching each target group identifies:

*Table 6 – Summary of the D&C tool addressed to the identified stakeholders' groups*

GROUP / D&C TOOL and Frequency (F) of the communication activity	Newsletter F - Every 6 months	Press releases F - After relevant events (see Table 4)	Short input papers F - After workshops and meetings	Project brochure F - M6 and following updates	Video F - 2 short clips	Indirect D&C through website and Social Media F - Permanent
GROUP 1 – health research organisations						
GROUP 2 – R&D health funders						
GROUP 3 – health system policy makers						
GROUP 4 – healthcare providers						
GROUP 5 – industry and private businesses						
GROUP 6 – civil society organisations						

## 2.6. Timeframe

The following Gantt chart summarises the timeframe of the most relevant D&C activities. Both website and social media, as well as bilateral meeting will take place all along the project.



## 3. Internal Communication

The internal communication is mainly being made by email and phone calls when needed.

Innovatec (P1), as project coordinator, is organising online meetings every two months. During these meetings, each WP leader and co-leader describes the status of development of its activities, as well as the next steps to be taken in the short and medium term. This assures that all the consortium is well aware of the project evolution and mitigation/contingency measures can be taken in advance, if needed.

Also, individual online meetings are being set up by WP/tasks participants.



So far, the following internal meeting have been held:

Table 7 – Internal meetings M1-M6

Meeting objective	Date	Partners involved
Kick off meeting	4 March 2021 (virtual)	All + External Advisory Board + EC Project Officer
WP 6 – to plan D&C activities for M1-M6	27 April 2021 (virtual)	INNO, ISCIII, ECSA-HC
WP2 – Task 2.1	Weekly meetings	INNO, ECITD
WP2 – task 2.2 and task 2.3	Weekly meetings	INNO, APHRC, NACOSTI, ECSA-HC
1 <sup>st</sup> Consortium meeting	13 May 2021 (virtual)	All partners
WP4 – to plan 1 <sup>st</sup> year activities	8 June 2021 (virtual)	IT-MoH, ISCIII, IRESSEF, AUDA-NEPAD and ANR
WP3 – to plan 1st year activities	7 June 2021 (virtual)	ANR, INNO, INSERM, SAMRC, RARS-IRESSEF
WP5 – to plan 1 <sup>st</sup> year activities	23 June 2021 (virtual)	ANR, ECRIN, INNO, IRESSEF, It-MoH
WP2/3 meeting – connection between the WPs	Several dates (virtual)	ANR, ECITD, INNO, INSERM, SAMRC
2 <sup>nd</sup> Consortium meeting	8 July 2021 (virtual)	All partners




Figure 6 – Screenshot of the virtual Kick off meeting of EU-Africa PerMed (4<sup>th</sup> March 2021)

D&C materials have been prepared to be shared with the partners in a **D&C Toolkit**:

- Deliverables Template (Annex I)
- Presentation Template (Annex II)
- EU funding visibility rules – obligations according to the Grant Agreement (Annex III)
- EU-Africa PerMed brochure (Annex IV)
- ERA PerMed brochure (Annex V)
- IC PerMed brochure (Annex VI)
- Project logos (see figure 1)



#### 4. Monitoring of the Dissemination and Communication

### 4.1. Key Performance Indicators

The Project Handbook (deliverable D1.1), submitted by M3, set some indicators to be measured and to evaluate the communication activities efficiency:

*Table 8 – KPIs for D&C activities*

EXAMPLES OF KPIs TO USE	MEASURE	TARGETS (M24)
<ul style="list-style-type: none"> <li>Nº registered users in the web</li> <li>Nº of visits, new and return</li> <li>Time on page, Conversion rate</li> </ul>	Every 6 months Google Analytics	Min 500+ interactions
<ul style="list-style-type: none"> <li>Nº of followers in Twitter/LinkedIn</li> <li>Comments, shares, likes in Twitter/LinkedIn</li> </ul>	Every 6 Months Social media analytics	Min 500+ followers in twitter
<ul style="list-style-type: none"> <li>Nº of registrations</li> <li>Nº assistants</li> <li>Geographical distribution of assistants</li> <li>Feedback from assistants (short evaluation survey)</li> </ul>	After/During event	Depends on the type of event (workshop, training event)
<ul style="list-style-type: none"> <li>Nº of people subscribed for the newsletters</li> <li>Nº of website downloads of public documents (flyer, deliverables, reports, newsletter)</li> <li>Nº openings/clicks of documents</li> </ul>	Every 6 months	Depending on Content, Min 100+ downloads on average
<ul style="list-style-type: none"> <li>Number of mentions/citations of EU-Africa PerMed in other initiatives communications (e.g., ICPeMed Family)</li> </ul>	Every 6 months	

#### 4.2.D&C Monitoring protocol

The efforts in D&C activities will be monitored every 6 months. Together with specific analytics monitoring software, the project partners will be requested to provide information to WP6 leaders. An excel sheet (see table 9) will be shared with all the partners in a shared repository, so they can easily report the activities taken concerning communication and dissemination.

*Table 9 – D&C Monitoring sheet to be gathered by WP6 leaders every 6 months*

[illegible]

#### 4.3. Obligations for communication actions

The requirements in terms of information on EU funding will be fulfilled all along the project. Basic instructions have been given to the partners within the D&C toolkit (see Annex III).

Any dissemination material will display the EU flag, as well as acknowledge of EU funding:



EU Africa PerMed has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 964333

Also, any communication activity will indicate that it reflects only the author's view and that HaDEA and the Commission are not responsible for any use that may be of the information it contains:

This document reflects only the author's view. Responsibility for the information and views expressed therein lies entirely with the authors. The European Commission is not responsible for any use that may be made of the information it contains

Given the nature of this Coordination and Support Action, it is not expected that the project will result in any infrastructure, equipment or major results such as patents. Nevertheless, partners will be advised by WP6 leader and coleader, if any of these materials arises from the action.

## 5. Conclusions and next steps

---

This D&C Plan provides EU-Africa PerMed with a solid framework, roadmap and practical tools and instructions in order to maximise the project impact through dissemination and communication. This constitutes an initial strategy, a living framework that will be updated as the project evolves.

The list of relevant stakeholders has been defined based on WP2 mapping activity, as well as the communication channels to reach them.

D&C communication channels such as the website and social media have been already set up, and some materials have been already elaborated.

Also, the next relevant events to be organised, such as stakeholders' workshop and summer schools, will be a golden opportunity to elaborate further materials based on the outcomes.

The D&C outcomes will be monitored, which will lead to place efforts wherever is more needed.



## Annexes

**Annex I** - Deliverables Template

**Annex II** - Presentation Template


**Annex III** - EU funding visibility rules – obligations according to the Grant Agreement

**Annex IV** – EU-Africa PerMed brochure

**Annex V** – ERA PerMed brochure

**Annex VI** – IC PerMed brochure





DX.X – Title of the  
deliverable

PARTNER RESPONSIBLE

DATE OF SUBMISSION

<b>Project Acronym</b>	EU-Africa PerMed	
<b>Project Title</b>	BUILDING LINKS BETWEEN EUROPE AND AFRICA IN PERSONALISED MEDICINE	
<b>Grant Agreement no.</b>	964333	
<b>Start date of the project</b>	01/02/2021	
<b>End date of the project</b>	31/01/2025	
<b>Work Package number</b>	WPX – XXXXXXXXXXXXXXXXXXXX	
<b>Deliverable Number</b>	XX	
<b>Deliverable title</b>	XXXXXXXXXXXXXXXXXXXXXXXXX	
<b>Lead Beneficiary</b>	XXXXXXXXXXXX	
<b>Due date</b>	MX (Month 202X)	
<b>Date of delivery</b>		
<b>Nature</b>	R (Report)	
<b>Dissemination level</b>	CO (Confidential) or PU (public)	
<p><b>DISCLAIMER</b>          This document reflects only the author's view. Responsibility for the information and views expressed therein lies entirely with the authors. The European Commission is not responsible for any use that may be made of the information it contains.</p>		
<b>Version</b>	<b>Contributors</b>	<b>Comments</b>



## TABLE OF CONTENT

1. OBJECTIVE .....	3
2. METHODOLOGY .....	3
2.1. SUBSECTION 2.1.....	3
2.2. SUBSECTION 2.2.....	3
3. RESULTS.....	3
4. CONCLUSIONS .....	4
5. NEXT STEPS AND RECOMMENDATIONS.....	4
ANNEXES .....	4

*‘Deliverables’ are additional outputs (e.g. information, special report, a technical diagram brochure, list, a software milestone or other building block of the action) that must be produced at a given moment during the action (normally not at the same time as the periodic/final reports).*

## Executive summary

*Brief summary of the **EU-Africa PerMed** project and the content of the deliverable.*

Half page to summarise:

- *Deliverable scope*
- *Work accomplished*
- *Key finding or conclusion*



## 1. Objective

---

*Describe the objective of the deliverable, its relationship with other WPs*

## 2. Methodology

---

*Methodology and work accomplished to elaborate the deliverable*

### 2.1. Subsection 2.1

### 2.2. Subsection 2.2

### 2.3. Subsection 2.3

## 3. Results


---

*Present and discuss the results obtained*

*If a table or figure has to be included, please, use the following format (or similar).*

*Table 1 – Describe the table content*

Text	Text	Text	Text
Text	Text	Text	Text
Text	Text	Text	Text



*Figure 1 – Describe the figure, picture, graph...*



#### 4. Conclusions

---

*Conclusions (half to one page)*

#### 5. Next steps and recommendations

---

*Next steps or recommendations (half to one page)*

#### Annexes

*If needed*

**Annex I** – Annex I title

**Annex II** - Annex II title

**Annex III** - Annex III title




# Title of the presentation

Event

Date

Speaker's name and institution



**BUILDING LINKS BETWEEN  
EUROPE AND AFRICA IN  
PERSONALISED MEDICINE**




EU Africa PerMed has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 964333

# Insert title of the slide

Text level 1

# Insert title of the slide

Text level 1



# Closing slide

Text




@EU\_AfricaPerMed



[www.euafrica-permed.eu](http://www.euafrica-permed.eu)

# Obligations on EU funding visibility



## Art. 29.4 – Information on EU funding – Obligation and right to use the EU emblem

Any dissemination of results must:

### a) Display the EU emblem [Available here](#)



*Use the EU emblem (flag) and not the logo of any of the European Institution or bodies*

### b) Include the following text



EU-Africa PerMed has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 964333

## Disclaimer excluding the Commission responsibility

This document reflects only the author's view. Responsibility for the information and views expressed therein lies entirely with the authors. The European Commission is not responsible for any use that may be made of the information it contains

### DISSEMINATION & COMMUNICATION MATERIALS

Newsletter, press releases



Presentations



Poster



Course, conferences material



If you plan to publish a **scientific publication**, ask first WP6 leaders

# EU + Africa PerMed

## BUILDING LINKS BETWEEN EUROPE AND AFRICA IN PERSONALISED MEDICINE



01/02/2021- 31/01/2025



2 million euros



Coordination and Support Action



INNOVATEC (ES)



### OBJECTIVE:


To integrate African countries into the [International Consortium of Personalised Medicine](https://www.icpermed.eu/) (<https://www.icpermed.eu/>) activities as a means to contribute to a successful implementation of [Personalized Medicine](#) in the [global context](#), fostering joint [PM projects and programmes](#) between [Europe and Africa](#), as well as strengthening bilateral [science, technology and innovation](#) relations in the area of health.

### PARTNERS:

#### EU partners



#### Africa partners



African Population and Health Research Center



EU-Africa PerMed has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 964333

Follow us:



<https://www.euafrica-permed.eu/>



@EU\_AfricaPerMed

# ERA PerMed

## ERA-Net Cofund in Personalised Medicine


**ERA PerMed** is a funding programme supported by the European Commission that promotes multidisciplinary research in the field of Personalised Medicine.



**ERA PerMed** aligns research activities and transforms **ICPerMed's** (International Consortium for Personalised Medicine) strategic reflections into reality.

### Joint transnational research funding

With 32 funding organisations from 23 countries and 5 regions, **ERA PerMed** is the largest ERA-Net in the health sector. More organisations and countries are joining the annual calls.



### Funding scheme based on joint efforts

Participating funding organisations



Through its annual calls, **ERA PerMed** is already funding 65 research projects with 345 teams and a total budget of about 76M€, including nearly 7M€ co-funding provided by the European Commission for the **JTC2018**.



**Projects funded**

**J**oint – Minimum 3 partners per consortium

**T**ransnational – from different countries

**C**alls – under competitive evaluation

### Next call for proposals



**Q1 2022**

**ERA PerMed** call for proposals will be drafted by Q3 2021

**Funding Entities** can join from now!!



[erapermed.isciii.es](https://erapermed.isciii.es)



[eranetpm@isciii.es](mailto:eranetpm@isciii.es)



@ERANET\_PerMed

Go to [erapermed.isciii.es/newsletter/follow-us/](https://erapermed.isciii.es/newsletter/follow-us/) to receive our **Newsletter**



ERA PerMed has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement No 779282



## Members of ICPeMed

Funding organisations from the following countries are involved in ICPeMed as members or observers:

Austria	Luxembourg
Brazil	Netherlands
Canada	Norway
Republic of Croatia	Poland
Cyprus	Portugal
Czech Republic	Republic of Moldova
Denmark	Romania
European Commission	Slovenia
Estonia	Spain
Finland	Sweden
France	Switzerland
Germany	Turkey
Hungary	
Ireland	
Israel	
Italy	
Lithuania	

More details can be found  
on the ICPe-Med website:  
[icpermed.eu](http://icpermed.eu)

## Contact

ICPerMed is supported by the ICPeMed Secretariat

E-Mail: [icpermed@dlr.de](mailto:icpermed@dlr.de)

Visit us on: [icpermed.eu](http://icpermed.eu)

## Imprint

Project coordinator of the Secretariat and publisher of  
this leaflet is DLR Project Management Agency

### Publisher

Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR)  
DLR Project Management Agency  
Linder Höhe  
51147 Köln

### Editor

DLR Project Management Agency

### Design

DLR Project Management Agency  
Print: DLR, Köln  
Bonn, November 2018

Picture credits:

ICPerMed's members map is a derivative of "World Map  
for Web Data Visualizations" by Al MacDonald, used  
under CC BY-SA 3.0.



The International Consortium for  
Personalised Medicine (ICPerMed)  
aims for a coordinated approach to  
personalised medicine.



**Personalised Medicine** “refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention”.

According to: Horizon 2020 and European Council Conclusions on personalised medicine for patients (2015/C 421/03)

## About ICPeMed

The International Consortium for Personalised Medicine (ICPeMed) brings together more than 40 European and international partners, representing ministries, funding agencies and the European Commission (EC).

ICPeMed works on coordinating and supporting research to develop personalised medicine approaches. Thereby, the central aim of ICPeMed is to align and encourage joint efforts in personalised medicine research and implementation on a European and international level.

ICPeMed developed a common Action Plan that sets out a discrete set of activities which form the current basis of the work programme for ICPeMed members and other interested funders.

## Workshops and Conferences

ICPeMed wants to bring together stakeholders who are active in the area of personalised medicine. To this end, each year, ICPeMed organises one large event. This event either is a thematically focused workshop (e.g. on “Innovative Concepts on Data Generation and use for Personalised Medicine Research” in Milan 2017) or a conference (e.g. on “Personalised Medicine in Action” in Berlin 2018).

## Mapping Database

The ICPeMed database on funding activities gives an overview of the actions in the field of personalised medicine performed in the ICPeMed member states and may assist interested users in finding suitable funding opportunities and information about potential funders in their respective country and/or region.

The ICPeMed Mapping Database is open to the public.

## Partnering Tool

The ICPeMed Partnering Tool offers you to search for research partners and to present your expertise to the personalised medicine research community. By completing and activating your profile you publish your partnering profile to all users and present your collaboration offers. The Partnering Tool assists you in finding suitable cooperation partners for future calls and thus facilitates networking among universities, research and patient organisations, SMEs, the industry and all other stakeholders interested in personalised medicine research.

## Annual Recognition

The ICPeMed „Best Practice in Personalised Medicine“ Recognition is granted annually and aims to recognise, encourage, promote and disseminate outstanding examples of best practices in personalised medicine. Designated applicants are invited to present their results at an international ICPeMed conference or workshop and will receive a non-cash support for the dissemination of the selected best practice examples.

## Stakeholder Group and Newsletter

Anyone who is interested in personalised medicine and the work of ICPeMed can register for the ICPeMed Stakeholder Group. Members of the Stakeholder Group will receive up-to-date information on ICPeMed, e.g. about upcoming events - like workshops or conferences - and new ICPeMed publications. In addition, you may want to register for the bi-annual ICPeMed Newsletter to receive information on a more aggregated level.

Find out more about ICPeMed's services such as the Mapping Database, Partnering Tool, Stakeholder Group and Newsletter:  
[icpermed.eu/en/services.php](https://icpermed.eu/en/services.php)

